Physician

Kanchana S. Anand, MD

According to 2025 Medicare claims, Kanchana Anand, MD (NPI: 1346398328) practices medical oncology in the Fresno, CA market, with the plurality of this provider's patient population coming from Fresno, CA. This provider's primary affiliated billing organization is CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC (NPI: 1083661607; TIN: 770324589) and primary practice location at 93720-3347.

Anand's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 17 traditional Medicare patients, billed 226 HCPCS/CPT codes, and received $9,844 in Medicare payments. Part D data shows 1,006 prescription claims across 182 beneficiaries totaling $3,784,863 in drug costs, led by Tagrisso (Osimertinib Mesylate). Open Payments data shows 4 records totaling $410. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing started with an early spike, then settled into a lower baseline, moving from $63,422 to $9,844. In contrast, Part D prescription costs have moved sharply higher in recent years, from $1,852,545 to $3,784,863. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$32K$63K2016 Medicare payment: $63,422 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $27,757 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $928 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $1,853 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $7,294 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $12,180 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $11,257 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $9,844 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016162,536$63,422
2017192,270$27,757
2018N/RN/RN/R
20191221$928
202017329$1,853
202121180$7,294
202221193$12,180
202322260$11,257
202417226$9,844

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$1.9M$3.8M2015 Drug cost: $1,852,545 (USD; Tot_Drug_Cst)2016 Drug cost: $1,561,148 (USD; Tot_Drug_Cst)2017 Drug cost: $667,865 (USD; Tot_Drug_Cst)2018 Drug cost: $783,252 (USD; Tot_Drug_Cst)2019 Drug cost: $813,729 (USD; Tot_Drug_Cst)2020 Drug cost: $918,234 (USD; Tot_Drug_Cst)2021 Drug cost: $1,488,463 (USD; Tot_Drug_Cst)2022 Drug cost: $2,547,489 (USD; Tot_Drug_Cst)2023 Drug cost: $3,300,888 (USD; Tot_Drug_Cst)2024 Drug cost: $3,784,863 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015131693$1,852,545
2016108579$1,561,148
2017122542$667,865
2018129513$783,252
2019107400$813,729
2020130583$918,234
2021150707$1,488,463
2022151752$2,547,489
2023179965$3,300,888
20241821,006$3,784,863

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Part B summary data is connected for 2024, but public code-level payment amounts are not available, so a Top 5 by total payments cannot be shown.

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
TagrissoOsimertinib Mesylate1153,450$1,978,315
LenvimaLenvatinib Mesylate25695$487,073
CalquenceAcalabrutinib Maleate25750$237,104
IbrancePalbociclib15315$232,244
XtandiEnzalutamide22660$201,926

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.4$410E.R. Squibb & Sons, L.L.C.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Kanchana S. Anand, MD?

Tedicare shows public-source Medicare data for Kanchana S. Anand, MD (NPI 1346398328), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kanchana S. Anand, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Kanchana S. Anand, MD?

Kanchana S. Anand, MD is linked to CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC (billing NPI 1083661607) in the available physician profile data.

Does Kanchana S. Anand, MD have Open Payments data?

Kanchana S. Anand, MD has 4 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.